Get the Stockscreener App
39.59
1.56%
0.61
After Hours:
39.59
Indivior Pharmaceuticals Inc stock is traded at $39.59, with a volume of 2.77M.
It is up +1.56% in the last 24 hours and up +29.93% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
See More
Previous Close:
$38.98
Open:
$39.19
24h Volume:
2.77M
Relative Volume:
1.12
Market Cap:
$4.83B
Revenue:
$1.29B
Net Income/Loss:
$251.00M
P/E Ratio:
20.05
EPS:
1.9744
Net Cash Flow:
$-193.86M
1W Performance:
+14.99%
1M Performance:
+29.93%
6M Performance:
+23.53%
1Y Performance:
+232.69%
1-Day Range:
$38.76
$39.90
1-Week Range:
$33.84
$40.02
52-Week Range:
$10.63
$40.02
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
39.59 | 4.75B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Indivior Pharmaceuticals Inc. (INDV) upgraded to strong buy: Here's what you should know - MSN
Why Indivior Pharmaceuticals (INDV) Is Up 9.8% After Raising 2026 Revenue Guidance And Earnings - Sahm
Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Here's why momentum in Indivior Pharmaceuticals Inc. (INDV) should keep going - MSN
Wall Street Analysts Predict a 27.76% Upside in Indivior Pharmaceuticals Inc. (INDV): Here's What You Should Know - Yahoo Finance
Indivior launches $175M accelerated share buyback - MSN
Indivior Announces $175 Million Accelerated Share Repurchase Agreement Under Existing Authorization - Minichart
Indivior Pharmaceuticals Inc. (INDV) Q1 earnings and revenues beat estimates - MSN
Indivior Announces $175 Million Accelerated Share Repurchase - TipRanks
Indivior starts $175M buyback with 3.7M shares due upfront - Stock Titan
Indivior Earnings Call Highlights SUBLOCADE-Fueled Momentum - The Globe and Mail
Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After A 214% One-Year Surge? - Yahoo Finance
Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After Its 214% One-Year Surge? - Sahm
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Bausch + Lomb Corporation (BLCO) and Indivior (INDV) - The Globe and Mail
Indivior Pharmaceuticals Q1 2026 Deep Dive: EPS Beats by 43.3%, Revenue Up 19% - AlphaStreet
Indivior (INDV) Q1 2026 Earnings Transcript - AOL.com
Here's Why Momentum in Indivior Pharmaceuticals Inc. (INDV) Should Keep going - Yahoo Finance
Indivior Posts Strong Q1 Results, Raises 2026 Outlook - The Globe and Mail
Indivior Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:INDV) 2026-04-30 - Seeking Alpha
Indivior Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Indivior Q1 2026 Earnings Call Transcript - MarketBeat
Indivior Pharmaceuticals Crushes Q1 2026 Profit Estimates by 43.3% - AlphaStreet
Indivior (INDV) Raises FY26 Guidance on Strong SUBLOCADE Performance - GuruFocus
Indivior (INDV) Reports Strong Q1 Revenue Growth - GuruFocus
Is Indivior (INDV) 56.5% Overvalued After Q1 2026? Revenue $317M - GuruFocus
Indivior Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Indivior Q1 2026 sees strong results, stock surges - Investing.com Canada
Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge - ChartMill
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q1 Revenue $317.0M, vs. FactSet Est of $272.8M - marketscreener.com
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.96 per Share, vs. FactSet Est of $0.66 - marketscreener.com
Indivior (NASDAQ: INDV) lifts 2026 guidance on SUBLOCADE growth and margin expansion - Stock Titan
Indivior發佈2026年第一季度財務業績，並上調2026年全年指導預期。 - Moomoo
Indivior stock hits all-time high at 38.14 USD By Investing.com - Investing.com Canada
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Indivior earnings on deck: Can SUBLOCADE momentum continue? By Investing.com - Investing.com Australia
Indivior earnings on deck: Can SUBLOCADE momentum continue? - Investing.com
Vanguard Portfolio Management reports 7.99M Indivior shares (INDV) - Stock Titan
Indivior plans $400M convertible senior notes offering - MSN
Evaluating Indivior Pharmaceuticals (NasdaqGS:INDV) After New ASAM 2026 Data On Sublocade Effectiveness - simplywall.st
How much upside is left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street analysts think 45.99% - MSN
Is Indivior Pharmaceuticals Inc (INDV) Overvalued After 3.2% Ral - GuruFocus
Vanguard Capital Management holds 5.35% of Indivior (NASDAQ: INDV) - Stock Titan
Indivior Pharmaceuticals (INDV) Jumps 6.2% to $35.27 - AlphaStreet
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout - TradingView
Indivior Pharmaceuticals Inc. (INDV): Billionaire Howard Marks Trims Stake - Insider Monkey
How Investors Are Reacting To Indivior (INDV) Real-World SUBLOCADE Data On Remission-Focused OUD Treatment - Yahoo Finance
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - MSN
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):